Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 599-606

  Tomita, Tetsu ^a   Norio, Yasui Furukori ^a   Sato, Yasushi ^a   Nakagami, Taku ^a   Tsuchimine, Shoko ^a   Kaneda, Ayako ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Antidepressants; Early response; Paroxetine; Receiver operating characteristic curve analysis; Sex differences

Indexed keywords

BROTIZOLAM; DIAZEPAM; PAROXETINE; SENNOSIDE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONSTIPATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT ACCURACY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 84898751013     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S57189     Document Type: Article

References (35)

1. Antonijevic IA. Depressive disorders - is it time to endorse different pathophysiologies? Psychoneuroendocrinology. 2006;31(1):1-15.
2. van Praag HM. Kraepelin, biological psychiatry, and beyond. Eur Arch Psychiatry Clin Neurosci. 2008;258 Suppl 2:29-32.
3. Lamers F, de Jonge P, Nolen WA, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71(12): 1582-1589.
4. Abela JR, Skitch SA, Auerbach RP, Adams P. The impact of parental borderline personality disorder on vulnerability to depression in children of affectively ill parents. J Pers Disord. 2005;19(1):68-83.
5. Arias B, Gutiérrez B, Pintor L, Gastó C, Fañanás L. Variability in the 5-HT(2A) receptor gene is associated with seasonal pattern in major depression. Mol Psychiatry. 2001;6(2):239-242.
6. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
7. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Res. 2009;174(2):152-157.
8. Jaworska N, Protzner A. Electrocortical features of depression and their clinical utility in assessing antidepressant treatment outcome. Can J Psychiatry. 2013;58(9):509-514.
9. Jaworska N, De Somma E, Blondeau C, et al. Auditory P3 in antidepressant pharmacotherapy treatment responders, non-responders and controls. Eur Neuropsychopharmacol. 2013;23(11): 1561-1569.
10. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol. 2005;25(4):318-324.
11. Morishita S, Arita S. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Eur Psychiatry. 2003;18(8):418-420.
12. Morishita S, Kinoshita T. Predictors of response to sertraline in patients with major depression. Hum Psychopharmacol. 2008;23(8): 647-651.
13. Inagaki T, Furuya M, Kawamukai T, et al. Prediction of response within the first 3 days to treatment with paroxetine for depression. Prim Care Companion J Clin Psychiatry. 2008;10(2):129-132.
14. Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8):1983-1989.
15. Henkel V, Seemüller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009;115(3):439-449.
16. Kok RM, van Baarsen C, Nolen WA, Heeren TJ. Early response as predictor of final remission in elderly depressed patients. Int J Geriatr Psychiatry. 2009;24(11):1299-1303.
17. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187-193.
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
19. Takahashi N, Tomita K, Higuchi T, Inada T. The inter-rater reliability of the Japanese version of the Montgomery-Asberg depression rating scale (MADRS) using a structured interview guide for MADRS (SIGMA). Hum Psychopharmacol. 2004;19(3):187-192.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
21. Burrows GD, McIntyre IM, Judd FK, Norman TR. Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness. J Clin Psychiatry. 1988;49 Suppl:18-22.
22. Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009;24(3):133-138.
23. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465.
24. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(Suppl 4):1-45.
25. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445-1452.
26. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43(5):503-511.
27. Ernst C, Angst J: The Zurich Study. XII: Sex differences in depression. Evidence from longitudinal epidemiological data. Eur Arch Psychiatry Clin Neurosci. 1992;241:222-230.
28. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry. 2000;157(8): 1243-1251.
29. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2-3):85-96.
30. Del Giudice M, Booth T, Irwing P. The distance between Mars and Venus: measuring global sex differences in personality. PLoS One. 2012;7(1):e29265.
31. Jovanovic H, Lundberg J, Karlsson P, et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage. 2008;39(3):1408-1419.
32. Parsey RV, Oquendo MA, Simpson NR, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res. 2002;954(2):173-182.
33. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol. 2002;23(1):41-100.
34. Higuchi H, Sato K, Naito S, et al. Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients. Neuropsychiatr Dis Treat. 2009;5:151-155.
35. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol. 2004;19(6):405-408.